Skip to main content

ASCIA News

  • AIFA Research Grants 2024
    Congratulations to the recipients of Allergy and Immunology Foundation of Australasia (AIFA) grants in 2024, who are listed on the AIFA website Since 2015, AIFA has awarded over $790,000 in grants to support 46 allergy and immunology research projects. AIFA is now seeking...
  • Consultations Currently Open for Feedback
    Consultations Currently Open for Feedback include: Draft National Nursing Workforce Strategy - Closing 20 October 2024 - This draft Strategy has been released for consultation and feedback from people and organisations with an interest in the nursing workforce. A...
  • ASCIA Quicklinks Update
    ASCIA Quicklinks were developed in March 2024 to improve access and reduce the need for printing of ASCIA website information, by using QR codes in an A4 format which can be printed or accessed online. The positive response to ASCIA Quicklinks has exceeded expectations. ASCIA...
  • ASCIA Submission - RACP Clinical Immunology and Allergy Advanced Training Curriculum - October 2024
    ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions. ASCIA submitted a response on 7 October 2024 to the Royal Australasian College of Physicians (RACP) call for feedback on the Development of the Clinical Immunology and...
  • Vale Dr Rob Loblay MBBS PhD FRACP - October 2024
    It is with great sadness we learnt that Dr Rob Loblay MBBS PhD FRACP passed away in early October 2024.  Dr Rob Loblay made significant contributions to ASCIA, particularly in the area of anaphylaxis management during his time as Chair of the ASCIA Anaphylaxis working...
  • Vale A/Prof Dan Czarny MBBS FRACP FRCP - May 2024
    It is with great sadness we learnt that A/Prof Dan Czarny MBBS FRACP FRCP passed away in early May 2024 at the age of 84.   A/Prof Dan Czarny made significant contributions to ASCIA, particularly as the 2nd ASCIA Past President from 1992 to 1994, after ASCIA was formed in...
  • New PBS Listed Treatment for ANCA Associated Vasculitis - October 2024
    In response to an application by CSL Seqirus to the Pharmaceutical Benefits Advisory Committee (PBAC), the Pharmaceutical Benefits Scheme (PBS) listing of Tavneos® (avacopan) that was recommended by the PBAC in March 2024 has come into effect on 1 October 2024. This...
  • Biologics in Severe Asthma - Change in PBS Criteria - October 2024
    In response to an application by GSK to the Pharmaceutical Benefits Advisory Committee (PBAC) to remove the oral corticosteroid (OCS) requirement to qualify for biologics in uncontrolled severe asthma, the Pharmaceutical Benefits Scheme (PBS) OCS criteria change that was...
ASCIA Member Login

Site last updated: 3 Oct 2024
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...